drugset / Trial / NCT01360177

Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

NCT01360177

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a treatment protocol designed to accompany the ongoing institutional 124I PET/CT pilot imaging study for patients with invasive breast cancer. Women whose tumors express NIS \[Na+I- symporter, sodium iodide symporter\] and demonstrate radioiodide uptake on 124I PET/CT scans will be eligible for 131I treatment if, (1) tumor dosimetry calculations yield a cumulative radiation dose of at least 30Gy in target tumor, (2) estimated cumulative thyroid irradiation is less than 500 cGy and, (3) the therapeutic dose of 131I is in the range of 25 to 100 mCi.

Timeline

Start
2010-07
Primary completion
2013-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule 75 ug Oral
Subject Liothyronine Small molecule 20 mg Oral
Subject Na134I Unknown 925 mbq
Subject Na134I Unknown 5550 mbq

Indications